How to buy BioNTech shares

BioNTech's COVID-19 vaccine (co-developed with Pfizer) has made headlines with the announcement of its 90% efficacy rate. But this early data is subject to change and the vaccine must pass rigorous testing by the Therapeutic Goods Administration’s (TGA) before it's approved for use in Australia.

BioNTech SE is a biotechnology business with stocks listed in the US. BioNTech shares (BNTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$102.6 – a decrease of -INF% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in BioNTech

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for BioNTech. Find the share by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$102.6, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BioNTech. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

BioNTech share price

Compare share trading platforms

Sort by:

Name	Product	Standard brokerage for US shares	Inactivity fee	Currency conversion fee	Markets
eToro Share Trading (US stocks) Finder Award		US$0	US$10 per month if there’s been no login for 12 months	0.50%	US shares	Zero brokerage share trading on US stocks with trades as low as $50. Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		US$0	$50 per quarter if you make fewer than three trades in that period	0.70%	ASX shares, Global shares	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		US$0	No	0.60%	ASX shares, Global shares, mFunds, ETFs	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy BioNTech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Shorting BioNTech shares

There are currently 3.8 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 4.9% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.

BioNTech's "short interest ratio" (SIR)

BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 1.4 million). BioNTech's SIR currently stands at 2.66. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 2660 shares are currently held short.

However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.

Find out more about how you can short BioNTech stock.

BioNTech share dividends

We're not expecting BioNTech to pay a dividend over the next 12 months.

BioNTech overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Frequently asked questions

• What percentage of BioNTech is owned by insiders or institutions?

  Currently 1.181% of BioNTech shares are held by insiders and 10.328% by institutions.

• When does the fiscal year end for BioNTech?

  BioNTech's fiscal year ends in December.

• Where is BioNTech based?

  BioNTech's address is: An der Goldgrube 12, Mainz, Germany, 55131

• What is BioNTech's ISIN number?

  BioNTech's international securities identification number is: US09075V1026

• What is BioNTech's CUSIP number?

  BioNTech's Committee on Uniform Securities Identification Procedures number is: 09075V102